Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CASCADE

Financiado

Cerrado

Cultivated Adult Stem Cells as Alternative for Damaged tissue

Rapid progress in stem cell research pave the way for the development and use of new cell therapy products in regenerative medicine. The objective of CASCADE is to provide the European Community with unique expertise which focuses... ver más

31/12/2011

EFS

5M€

Presupuesto del proyecto: 5M€

Líder del proyecto

ETABLISSEMENT FRANCAIS DU SANG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 14 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2011-12-31 No tenemos la información de la convocatoria

0% 58% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

14 Participantes

EFS

0.00€ | Lider

CNRS

N.D. | Participante

USAAR

N.D. | Participante

UKHD

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

ETABLISSEMENT FRANCAIS DU SANG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 5M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Rapid progress in stem cell research pave the way for the development and use of new cell therapy products in regenerative medicine. The objective of CASCADE is to provide the European Community with unique expertise which focuses on the GMP production of mesenchymal stem cells (MSC) and their use in treating skin and corneal wounds, so that quality and safety criteria are paramount and match therapeutic expectations. Commencing with known procedures, CASCADE will develop innovative technologies based on the expertise of its partners. Among our research themes, the specific issue of multiple recipients and universal donors will be investigated. To this end, human MSC will be derived from 4 tissues, bone marrow, fat tissue, cord blood and amniotic membrane, according to good manufacturing practice (GMP). Phenotypic identity of GMP produced MSC, their genetic status and their potential for transformation will constitute the basis for establishing standards for controlling cell production. The efficacy of GMP produced MSC will be tested in in vitro and in vivo models, and the immunological consequences of their use will be studied. Moreover, during the whole CASCADE initiative, ethical and legal issues raised as a result of MSC therapies will be considered. Direct collaboration with two clinical networks will allow CASCADE to finely tune production specifications, and define optimal clinical protocols for these MSC-based cellular therapies. CASCADE will therefore gather together leading European cell therapy laboratories with unrivalled expertise in the production of therapeutic cells and in MSC biology, four SMEs with specific know-how in GMP production of cells and two clinical networks in dermatology and ophthalmology. The outcome will be a consortium that encompasses all the technologies and skills required to efficiently develop innovative technologies for the production of clinical grade MSC and to translate this production into a cell drug to repair wounds.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores